[1]谭永华,蔡江霞,刘慧利,等.信迪利单抗治疗中晚期肝细胞癌的疗效及安全性[J].介入放射学杂志,2023,32(08):750-754.
　TAN Yonghua,CAI Jiangxia,LIU Huili,et al.Sintilimab for the treatment of advanced hepatocellular carcinoma： analysis of its clinical efficacy and safety[J].journal interventional radiology,2023,32(08):750-754.
点击复制

信迪利单抗治疗中晚期肝细胞癌的疗效及安全性()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年08
页码:
750-754
栏目:
肿瘤介入
出版日期:
2023-08-29

文章信息/Info

Title:
Sintilimab for the treatment of advanced hepatocellular carcinoma： analysis of its clinical efficacy and safety
作者:
谭永华;  蔡江霞;  刘慧利;  刘 煜;  张 静
Author(s):
TAN Yonghua;  CAI Jiangxia;  LIU Huili;  LIU Yu;  ZHANG Jing.
Interventional Department， People’s Hospital of Bayingolin Mongolian Autonomous Prefecture， Korla， Xinjiang Uygur Autonomous Region 841099， China
关键词:
【关键词】 肝细胞癌;  信迪利单抗;  免疫治疗
文献标志码:
A
摘要:
【摘要】 目的 评价信迪利单抗治疗晚期肝细胞癌（hepatocellular carcinoma，HCC）的疗效及其安全性。方法 收集2018年1月至2021年5月巴州人民医院收治的晚期不可切除HCC患者70例，随机分为对照组38例和联合组32例。对照组采用TACE+索拉非尼方案；联合组采用TACE+索拉非尼+信迪利单抗，于TACE术后第3天静脉滴注信迪利单抗200 mg，每3周给药1次。观察无进展生存时间（progression- free survival，PFS）、总生存期（overall survival，OS）、客观缓解率（objective response rate，ORR）、疾病控制率（disease control rate，DCR）、不良反应、甲胎蛋白（AFP）及生活质量（quality of life， QOL）评分。结果 联合组的PFS为11.90（6.46，17.34）个月，高于对照组的4.70（0，11.34）个月，差异有统计学意义（Z=4.013，P=0.045）。联合组的OS未到达足够50%死亡的数据，对照组为11.90（0，23.83）个月，差异有统计学意义（Z=4.511，P=0.045）。联合组ORR 和 DCR分别为34.3%和75.0%，均高于对照组的31.6%和71.1%，但差异无统计学意义（χ2=0.062、0.137，P=0.804、0.711）。联合组中甲状腺功能减低、低蛋白血症、白细胞减少的比例分别为28.1%、34.4%、34.4%，高于对照组的7.9%、10.5%、13.2%，差异有统计学意义（χ2=5.005、5.868、4.435，P=0.025、0.015、0.035）。随访2～24周，两组患者QOL评分有逐渐增高的趋势，但是组内比较，差异均无统计学意义（F=1.437、1.495，P=0.201、0.181）；AFP逐渐下降，组内比较差异均有统计学意义（Z=29.474、51.195，均P＜0.01）。随访第0、2、4、6周时，对照组与联合组的AFP比较，差异均无统计学意义（P＞0.05），但随访第8、16、24周时，联合组低于对照组，且差异均有统计学意义（Z=-2.247、-2.665、-3.130，P=0.025、0.008、0.002）。结论 TACE+索拉非尼+信迪利单抗方案对晚期HCC的疗效优于TACE+索拉非尼方案，且安全性较好。

参考文献/References:

［1］ Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialp［J］. Gut,2020,69:1492- 1501.
［2］ Finn R, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med, 2020,382:1894- 1905.
［3］ Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD- 1 signaling pathway［J］. J Biomed Sci, 2017, 24: 26.
［4］ Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT- 15): multicentre, randomised, double blind, phase 3 trial［J］. BMJ, 2022,377:e068714.
［5］ 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）［J］． 临床肝胆病杂志， 2020， 36:277- 292.
［6］ Forner A, Reig M, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2018, 391:1301- 1314.
［7］ Meier V, Ramadori G. Clinical staging of hepatocellular carcinoma［J］. Dig Dis,2009,27:131- 141.
［8］ Lencioni R，Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis，2010，30：52- 60.
［9］ Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update［J］.Hepatol,2022,76:681- 693.
［10］ Salmaninejad A, Valilou SF, Shabgah AG, et al. PD- 1/PD- L1 pathway: basic biology and role in cancer immunotherapy［J］. J Cell Physiol，2019，234：16824- 16837.
［11］ Han Y, Liu D, Li L. PD- 1/PD- L1 pathway: current researches in cancer［J］. Am J Cancer Res， 2020，10：727- 742.
［12］ 郑桂丽, 梁秀菊, 董 敏,等. PD- 1抑制剂联合FOLFOX4化疗方案治疗晚期胃癌的效果［J］. 中国医药导报, 2021, 18:98- 101.
［13］ Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD- 1 blockade is critical to effective combination immunotherapy with anti- OX40［J］. Clin Cancer Res, 2017, 23: 6165- 6177.
［14］ Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD- 1+ CD8+ T cell pool with predictive potential in non- small- cell lung cancer treated with PD- 1 blockade［J］. Nat Med, 2018, 24: 994- 1004.
［15］ Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first- line treatment of metastatic nonsquamous NSCLC［J］. N Engl J Med, 2018, 378:2288- 2301.
［16］ Shigeta K, Datta M, Hato T, et al. Dual PD- 1 and VEGFR- 2 blockade promotes vascular normalization and enhances anti- tumor immune responses in HCC［J］. Hepatology, 2020, 71: 1247- 1261.
［17］ Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial［J］.Lancet Oncol, 2018, 19: 940?952.
［18］ Llovet J, Shepard KV, Finn RS, et al. A phase ibtrial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma(uHCC): updated results［J］. Ann Oncol,2019, 30:v286-v287.
［19］ Reck M, Rodriguez- Abreu D, Robinson AG, et al. Five- year outcomes with pembrolizumab versus chemotherapy for metastatic non- small- cell lung cancer with PD- L1 tumor proportion score≥50［J］. J Clin Oncol,2021, 39:2339- 2349.
［20］ Li D, Xu L, Ji J, et al. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: a prospective, open- label, single- arm, phase Ⅱclinical study［J］. Front Immunol, 2022, 13:944062.
［21］ 何晶晶, 杨欣静, 范卫君. 经导管动脉灌注PD- 1单抗治疗恶性肿瘤所致免疫相关不良反应［J］. 介入放射学杂志, 2022, 31:171- 175.
［22］ 何斯怡, 张 敏, 许 震, 等. 信迪利单抗联合化疗治疗非小细胞肺癌的效果及对免疫功能指标的影响［J］. 中国实用医药, 2021, 16:12- 15.
［23］ Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real- world cohort of hepatitis B virus associated hepatocellular carcinoma patientsp［J］. Ann Transl Med， 2020， 8:1187.
［24］ Dai L, Cai X, Mugaanyi J, et al. Therapeutic effectiveness and safety of sintilimab- dominated triple therapy in unresectable hepatocellular carcinoma［J］. Sci Rep，2021，11：19711.
［25］ Xue J, Astère M, Zhong M, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non- small cell lung cancer: a meta- analysis［J］. Onco Targets Ther，2018， 11：6119- 6128.
［26］ Sun X, Mei J, Lin W, et al. Reductions in AFP and PIVKA- Ⅱ can predict the efficiency of anti- PD- 1 immunotherapy in HCC patients［J］. BMC cancer, 2021, 21：775

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(08):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(08):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(08):206.
[4]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(08):469.
[5]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(08):974.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(08):636.
[7]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(08):520.
[8]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(08):769.
[9]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(08):381.
[10]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(08):908.

备注/Memo

备注/Memo:
（收稿日期：2022- 10- 27）
（本文编辑：新 宇）
更新日期/Last Update: 2023-08-29